{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:05:56Z","timestamp":1790175956161,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2012,9,20]],"date-time":"2012-09-20T00:00:00Z","timestamp":1348099200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Therapy"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s12325-012-0052-6","type":"journal-article","created":{"date-parts":[[2012,9,21]],"date-time":"2012-09-21T12:15:51Z","timestamp":1348229751000},"page":"815-825","source":"Crossref","is-referenced-by-count":35,"title":["Lurasidone in Schizophrenia: New Information About Dosage and Place in Therapy"],"prefix":"10.1007","volume":"29","author":[{"given":"Leslie","family":"Citrome","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,20]]},"reference":[{"key":"52_CR1","unstructured":"United States Food and Drug Administration. FDA approves Latuda to treat schizophrenia in adults. Press release, October 28, 2010. Available at: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm231512.htm . Accessed Jun 20 2012."},{"key":"52_CR2","unstructured":"Sunovion Pharmaceuticals Canada Inc. Sunovion Pharmaceuticals Canada Inc. announces Health Canada approval of once-daily LATUDA? (lurasidone HCl) for the treatment of patients with schizophrenia. Press release, June 15, 2012. Available at: http:\/\/www.sunovion.ca\/news\/pressReleases\/20120615.pdf . Accessed Jun 20 2012."},{"key":"52_CR3","unstructured":"Sunovion Pharmaceuticals Inc. Latuda: US Package Insert for Latuda (lurasidone HCl) tablets for oral use. May 2012. Available at: http:\/\/www.latuda.com\/LatudaPrescribingInformation.pdf . Accessed Sept 5 2012."},{"key":"52_CR4","unstructured":"Sunovion Pharmaceuticals Canada Inc. Latuda: Product Monograph for Latuda (lurasidone HCl) 40 mg, 80 mg and 120 mg film-coated tablets. 18 June 2012. Available at: http:\/\/www.sunovion.ca\/monographs\/latuda.pdf . Accessed Jun 20 2012."},{"key":"52_CR5","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1517\/14656560903061309","volume":"10","author":"J. Volavka","year":"2009","unstructured":"Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother. 2009;10:1917\u20131928.","journal-title":"Expert Opin Pharmacother"},{"key":"52_CR6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1742-1241.2010.02587.x","volume":"65","author":"L. Citrome","year":"2011","unstructured":"Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract. 2011;65:189\u2013210.","journal-title":"Int J Clin Pract"},{"key":"52_CR7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3371\/CSRP.4.4.5","volume":"4","author":"L. Citrome","year":"2011","unstructured":"Citrome L. Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic. Clin Schizophr Relat Psychoses. 2011;4:251\u2013257.","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"52_CR8","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1586\/ern.12.7","volume":"12","author":"J.T. Kantrowitz","year":"2012","unstructured":"Kantrowitz JT, Citrome L. Lurasidone for schizophrenia: what\u2019s different? Expert Rev Neurother. 2012;12:265\u2013273.","journal-title":"Expert Rev Neurother"},{"key":"52_CR9","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1517\/13543780903286388","volume":"18","author":"J.M. Meyer","year":"2009","unstructured":"Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs. 2009;18:1715\u20131726.","journal-title":"Expert Opin Investig Drugs"},{"key":"52_CR10","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s12325-009-0055-0","volume":"26","author":"L. Citrome","year":"2009","unstructured":"Citrome L. Using oral ziprasidone effectively: the food effect and dose-response. Adv Ther. 2009;26:739\u2013748.","journal-title":"Adv Ther"},{"key":"52_CR11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4088\/JCP.08m04905","volume":"70","author":"M. Nakamura","year":"2009","unstructured":"Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a doubleblind, placebo-controlled trial. J Clin Psychiatry. 2009;70:829\u2013836.","journal-title":"J Clin Psychiatry"},{"key":"52_CR12","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1176\/appi.ajp.2011.10060907","volume":"168","author":"H.Y. Meltzer","year":"2011","unstructured":"Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011;168:957\u2013967.","journal-title":"Am J Psychiatry"},{"key":"52_CR13","doi-asserted-by":"crossref","unstructured":"Ogasa M, Kimura T, Nakamura M, Guarino J. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl). 2012. [Epub ahead of print].","DOI":"10.1007\/s00213-012-2838-2"},{"issue":"Suppl.1","key":"52_CR14","first-page":"S313","volume":"35","author":"A. Loebel","year":"2011","unstructured":"Loebel A, Cucchiaro J, Pikalov A, et al. Lurasidone in the treatment of acute schizophrenia: results of the double-blind, placebo-controlled, 6-week, PEARL 3 trial. Neuropsychopharmacology. 2011;35(Suppl. 1):S313\u2013S314.","journal-title":"Neuropsychopharmacology"},{"key":"52_CR15","unstructured":"United States Food and Drug Administration. Drug approval package. Latuda (lurasidone hydrochloride) tablets. Available at: www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/200603Orig1s000TOC.cfm . Accessed Jun 20 2012."},{"key":"52_CR16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2011.04.008","volume":"132","author":"S. Potkin","year":"2011","unstructured":"Potkin S, Ogasa M, Cucchiaro J, Loebel A. Doubleblind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr Res. 2011;132:101\u2013107.","journal-title":"Schizophr Res"},{"key":"52_CR17","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3371\/CSRP.6.2.5","volume":"6","author":"L. Citrome","year":"2012","unstructured":"Citrome L. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Clin Schizophr Relat Psychoses. 2012;6:76\u201385.","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"52_CR18","unstructured":"McEvoy JP, Citrome L, Hernandez D, et al. Switching to lurasidone in patients with schizophrenia: tolerability and effectiveness of three switch strategies. Poster Presentation NR6-46, American Psychiatric Association 165th Annual Meeting; May 5\u20139, 2012; Philadelphia, PA."},{"key":"52_CR19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/YIC.0b013e32835281ef","volume":"27","author":"L. Citrome","year":"2012","unstructured":"Citrome L, Cucchiaro J, Sarma K, et al. Longterm safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, activecontrolled study. Int Clin Psychopharmacol. 2012;27:165\u2013176.","journal-title":"Int Clin Psychopharmacol"},{"key":"52_CR20","doi-asserted-by":"crossref","unstructured":"Loebel A, Cucchiaro J, Xu J, Sarma K, Pikalov A, Kane JM. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind study. Poster Presentation NR6-36, American Psychiatric Association 165th Annual Meeting; May 5\u20139, 2012; Philadelphia, PA.","DOI":"10.1016\/S0920-9964(12)70779-X"},{"key":"52_CR21","unstructured":"Stahl SM, Cucchiaro J, Simonelli D, Severs J, Loebel A. Long-term safety and tolerability of lurasidone in patients with schizophrenia: results of a 6-month, open-label extension study. Poster Presentation NR6-58, American Psychiatric Association 164th Annual Meeting; May 14\u201318, 2011; Honolulu, HI."},{"issue":"2","key":"52_CR22","first-page":"153","volume":"123","author":"L. Citrome","year":"2011","unstructured":"Citrome L. Iloperidone, asenapine and lurasidone. A brief overview of three new second-generation antipsychotics. Postgrad Med. 2011;123(2):153\u2013162.","journal-title":"A brief overview of three new second-generation antipsychotics. Postgrad Med"},{"key":"52_CR23","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1517\/14656566.2011.626767","volume":"13","author":"L. Citrome","year":"2012","unstructured":"Citrome L, Nasrallah HA. On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. Expert Opin Pharmacother. 2012;13:1599\u20131613.","journal-title":"Expert Opin Pharmacother"},{"key":"52_CR24","unstructured":"Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy for the treatment of bipolar I depression: results of a 6-week, double-blind, placebo-controlled study. Poster Presentation NR4-58, American Psychiatric Association 165th Annual Meeting; May 5\u20139, 2012; Philadelphia, PA."},{"key":"52_CR25","unstructured":"Loebel A, Cucchiaro J, Silva R, et al. Lurasidone adjunctive to lithium or valproate for the treatment of bipolar I depression: results of a 6-week, double-blind, placebo-controlled study. Poster Presentation NR4-29, American Psychiatric Association 165th Annual Meeting; May 5\u20139, 2012; Philadelphia, PA."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-012-0052-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-012-0052-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-012-0052-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T03:43:46Z","timestamp":1562211826000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-012-0052-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,20]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["52"],"URL":"https:\/\/doi.org\/10.1007\/s12325-012-0052-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,20]]}}}